EGFR and non-small cell lung carcinoma: This combination was also evaluated in Japanese (WJOG 8715L) and European (BOOSTER) patients with EGFR T790M-mutant NSCLC who developed disease progression after a first- or second-generation EGFR TKI [53,54].